150668-82-9

Usage

Uses

Used in Pharmaceutical Industry:
3,3-Dimethylpiperidin-4-one is used as a building block for the development of various pharmaceuticals due to its unique chemical structure and reactivity. Its ability to form stable intermediates and participate in organic synthesis reactions contributes to the creation of new and innovative drug molecules.
Used in Agrochemical Industry:
In the agrochemical industry, 3,3-dimethylpiperidin-4-one is utilized as a key component in the synthesis of various agrochemicals. Its reactivity and compatibility with other chemical compounds make it an essential ingredient in the development of effective and efficient agrochemical products.
Used in Organic Synthesis:
3,3-Dimethylpiperidin-4-one is used as a reagent in organic synthesis for its ability to participate in a wide range of chemical reactions. Its versatility allows chemists to create new compounds and molecules with specific properties and applications.
Used as a Catalyst in Chemical Reactions:
3,3-DIMETHYLPIPERIDIN-4-ONE is also used as a catalyst in various chemical reactions, enhancing the reaction rates and improving the overall efficiency of the process. Its catalytic properties make it a valuable tool in the synthesis of complex organic molecules.

Upstream product

• 173186-91-9 N-benzyl-3,3-dimethylpiperidine-4-one 
• 324769-06-4 tert-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate 

Downstream Products

• 324769-06-4 tert-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate 
• 1247885-05-7 3,3-dimethyl-1-tosylpiperidin-4-one 
• 936329-33-8 1-(4-chlorobenzyl)-3,3-dimethylpiperidine-4-one 

Relevant academic research and scientific papers

Syntheses of isotopically labeled versions and major metabolites of CCR1 antagonist MLN3897

MLN3897 citrate is a novel CCR1 antagonist that was taken into development for treatment of chronic inflammatory diseases such as multiple sclerosis and rheumatoid arthritis. Non-clinical data had indicated extensive metabolism of MLN3897 via N-dealkylati

CHEMICAL COMPOUNDS

The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the tr

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA

The invention provides 1 -benzyl- 4 -piperidinamines of the general formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory diseses such a

Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments

This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.

Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments

This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.